We strongly support this amendment, and I congratulate the gentlewoman for offering it. Mr. Chairman, I yield 3 minutes to the gentleman from Texas (Mr. Barton), the former chairman, ranking member, subcommittee chair, ranking member, and…

Although I am not in opposition to the amendment, I claim the time. The Acting CHAIR. Without objection, the gentleman from Michigan is recognized for 5 minutes. There was no objection.

I demand a recorded vote. The Acting CHAIR. Pursuant to clause 6 of rule XVIII, further proceedings on the amendment offered by the gentlewoman from California will be postponed. Amendment No. 4 Offered by Mr. Castro of Texas The Acting…

Could I ask how much time is remaining on each side? The Acting CHAIR. The gentleman from Michigan has 2 minutes remaining, and the gentlewoman from California has 1 minute remaining.

I claim time in opposition to the amendment. The Acting CHAIR. The gentleman from Michigan is recognized for 5 minutes.

I do rise in support of this important amendment that, with Mr. Young and Dr. Harris, would authorize the NIH to conduct a prize program. The intent of the amendment is, in fact, to incentivize health innovation by offering competitors the…

Let me just say to the gentleman from California, it is paid for. CBO has certified that all of it is paid for. Madam Chair, I yield the balance of my time to the gentlewoman from Indiana (Mrs. Brooks), a member of the committee.

I claim time in opposition, although I do not oppose this amendment. The Acting CHAIR. Without objection, the gentleman from Michigan is recognized for 5 minutes. There was no objection.

We support this amendment. I think that it is important. It would include underrepresented individuals in the sciences in the NIH report on efforts to attract, retain, and develop emerging scientists. It is important to ensure that the NIH…

I yield myself the balance of the time to close. I won't use 12\1/2\ minutes, I don't think. Mr. Chair, I appreciate you being here tonight and the Members, knowing that we are going to debate a number of amendments and vote on final…

If I might ask, how much time do I have remaining? The CHAIR. The gentleman from Michigan has 12\1/2\ minutes remaining.

I include the Committee on Energy and Commerce exchange of letters with the Committee on Ways and Means and the Committee on Science, Space, and Technology. House of Representatives, Committee on Science, Space, and Technology, Washington…

As we all know, we launched this bipartisan effort about a year and a half ago, and with tomorrow's House vote, we mark a very important milestone in our quest for 21st century cures, one step closer to the finish line. There have been so…

America's energy picture has changed dramatically, and this committee has been working hard to keep pace.

We need to get this policy right. Yes, we do.

I often remind you all that I'm from the auto State. It's because folks from Michigan take special pride in manufacturing vehicles that offer safety, comfort, efficiency, and superior driving experiences to consumers throughout the United…

Today we fight to keep electricity affordable with the Ratepayer Protection Act, a bill that protects folks all across the country from the potential rate increases and reliability risks that experts predict will occur under the EPA's…

Today, roughly one in three Medicaid dollars is spent through an 1115 waiver approved by the Secretary of HHS.

This year, the Medicaid Program turns 50. Over that half a century, Medicaid has provided critical health coverage for some of our Nation's most vulnerable populations.

At the end of the day, it is about ensuring our most vulnerable receive the care that they deserve.

This is a long time coming. The breakthrough bipartisan bill before us today is the culmination of a multi-year, multi-Congress effort to modernize our decades-old chemical safety laws. The Toxic Substances Control Act, which was signed…

Right now as we speak, the international community is meeting in Argentina to discuss the state of the Internet around the globe. We have an opportunity today to send a loud and clear message to those gathered in Buenos Aires: that the…

CMS has a duty, both to patients and taxpayers, to States, all stakeholders, to do more to increase the transparency, accountability, and consistency of their approval process.

There are a number of state-specific labeling requirements that are inconsistent, potentially confusing to consumers.

It is important for the public to be engaged.